Format

Send to

Choose Destination
Cardiovasc Hematol Disord Drug Targets. 2017;17(3):180-184. doi: 10.2174/1871529X18666171227152937.

Platelets Structure, Function and Modulator Capacity in Replacement Therapy.

Author information

1
ISEP, Instituto Superior de Engenharia do Porto, Instituto Politecnico do Porto, Porto, Portugal.
2
INSA, National Institute of Health Dr. Ricardo Jorge, Department of Health Promotion and Chronic Diseases, Rua Alexandre Herculano, 321, 4000-055 Porto, Portugal.
3
i3S, Instituto de Investigação e Inovacão da Universidade do Porto, Porto, Portugal.

Abstract

INTRODUCTION:

Patients with severe thrombocytopenia are presumed to be at increased risk for bleeding, and consequently it has been a standard practice for the past four decades to give allogeneic platelet transfusions to severely thrombocytopenic patients as supportive care. Platelet transfusions may be given either prophylactically to reduce the risk of bleeding, in the absence of clinical hemorrhage (prophylactic transfusions), or to control active bleeding when present (therapeutic transfusions).

CONCLUSION:

Here we review the structure and function of platelets and discuss the mechanisms of alloimmunization to platelet transfusion.

KEYWORDS:

Alloimmunization; bone marrow.; hemostasis; platelet refractoriness; platelet transfusion; stem cells

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center